← Leaderboards
Graham P Allaway
Panacos Pharmaceuticals, Inc.
$3,192,910
Attributed
$3,192,910
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,192,910 · 3
By mechanism
R44$3,067,319 · 2
R43$125,591 · 1
Top collaborators
No co-investigators on record.
Most similar at Panacos Pharmaceuticals, Inc.
Same institution · by research overlap
- Carl T. Wild$690,847
- Karl Salzwedel$513,175
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionPharmacokineticsAntiaids AgentPlant ExtractsHuman Immunodeficiency VirusMicrosomesClinical Trial Phase ILiver CellsLaboratory RatScid MouseTerpenesDrug MetabolismAntiviral AgentsTriterpenesBiological ProductsClinical ResearchDogsDrug Discovery /IsolationDrug Screening /EvaluationExperimental DesignsHiv InfectionsHuman Immunodeficiency Virus 1Human SubjectPatient Oriented Research
Grant awards (6)
Development of DSB, a novel potent HIV inhibitor$575,847
R44 · FY2005 · AI
Development of DSB, a novel potent HIV inhibitor$840,027
R44 · FY2004 · AI
Development of DSB, a novel potent HIV inhibitor$783,893
R44 · FY2003 · AI
NATURAL PRODUCT DERIVATIVES THAT POTENTLY INHIBIT HIV-1$437,061
R44 · FY2002 · AI
DEVELOPMENT FOR DSB, A NOVEL POTENT HIV INHIBITOR$125,591
R43 · FY2002 · AI
NATURAL PRODUCT DERIVATIVES THAT POTENTLY INHIBIT HIV-1$430,491
R44 · FY2001 · AI